Friedreich's Ataxia Program Research

This study to evaluate the causes of cell death in FA and to create cell lines that can be shared with other companies or researchers for FA research is sponsored by FARA.

CHOP's FA research study examining the contribution of cardiomyopathy to disease progression in FA patients is funded by FARA and the NIH.

CHOP's to retrospectively assess disease progression in Friedreich’s ataxia (FRDA) patients is funded by FARA.

The purpose of this FARA-funded study is to evaluate the causes of cell death in Friedreich's ataxia.

CHOP's mobile phone measurements study is funded by the Friedreich's Ataxia Research Alliance (FARA).

The goal of this study, funded by the Friedreich Ataxia Research Alliance (FARA), is to develop measures to assess short-term disease progression in Friedreich's ataxia (FA).

This study follows Friedreich ataxia progression in children twice a year over the course of three years.

Co-investigated by HUP, our optical coherence tomography observational study is meant to help characterize the visual dysfunction sometimes seen in Friedreich's ataxia.

This multi-site, placebo-controlled study for RTA 408 in Friedreich's ataxia is sponsored by Reata Pharmaceuticals.